| Full text | |
| Author(s): Show less - |
Caridha, Diana
;
Vesely, Brian
;
van Bocxlaer, Katrien
;
Arana, Byron
;
Mowbray, Charles E.
;
Rafati, Sima
;
Uliana, Silvia
;
Reguera, Rosa
;
Kreishman-Deitrick, Mara
;
Sciotti, Richard
;
Buffet, Pierre
;
Croft, Simon L.
Total Authors: 12
|
| Document type: | Journal article |
| Source: | INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE; v. 11, p. 12-pg., 2019-12-01. |
| Abstract | |
Although there have been significant advances in the treatment of visceral leishmaniasis (VL) and several novel compounds are currently in pre-clinical and clinical development for this manifestation of leishmaniasis, there have been limited advances in drug research and development (R & D) for cutaneous leishmaniasis (CL). Here we review the need for new treatments for CL, describe in vitro and in vivo assays, models and approaches taken over the past decade to establish a pathway for the discovery, and pre-clinical development of new drugs for CL. These recent advances include novel mouse models of infection using bioluminescent Leishmania, the introduction of PK/PD approaches to skin infection, and defined pre-clinical candidate profiles. (AU) | |
| FAPESP's process: | 15/09080-2 - Evaluation of candidate drugs for the treatment of Leishmaniasis in Brazil |
| Grantee: | Silvia Reni Bortolin Uliana |
| Support Opportunities: | Regular Research Grants |